YNYimin Niu

Yimin Niu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yimin Niu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Huihui Shi

    Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.and School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

    3 shared publications
  • Jianhua Zhu

    School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

    3 shared publications
  • Yang Li

    School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

    3 shared publications
  • Yang Liu

    Department of Pharmaceutics, School of Pharmacy

    3 shared publications
  • Qiang Huo

    School of Pharmacy, Bengbu Medical College, Bengbu 233030, China

    2 shared publications
  • Fen Yang

    School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China

    1 shared publication

Latest Publications

  • Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors

    by Huihui Shi, Ming Xu, Jianhua Zhu, Yang Li, Zhiyu He, Yuxia Zhang, Qunwei Xu, Yimin Niu, Yang Liu

    Recently, ultra-small platinum nanoparticles (USPtNs) have been found that can kill cancer cells by leaching Pt ions into acidic organelles, such as cell endosomes or lysosomes. Unfortunately, tumor-specific accumulation is difficult to achieve with such platinum nanodrugs of less than 5 nm due to their short half-life in vivo and broad range of toxicity to normal tissues. Programmable multi-drug release for combinational chemotherapy by hierarchical nanostructures provides a promising solution for cancer-targeted therapy. Herein, we demonstrated a pH/redox dual stimuli-responsive clustered nanoparticle as a vehicle for simultaneously delivering USPtNs and gemcitabine (GEM) to treat non-small-cell lung cancer. The clustered nanoparticle (denoted as GP-NA) was composed of disulfide-bond-containing GEM-grafted copolymers (PEG-b-P(LL-g-GEM)), pH-sensitive polypeptides (OAPI), and USPtNs. Such a hybrid nanosystem completes multiple tasks inside cancer cells, which include the generation of cytotoxic Pt ions in response to lysosomal acidic environments and the subsequent release of GEM in cytoplasmic reduction environments. Compared with non-acid-sensitive nanoparticles or free drugs, GP-NA exhibited cumulative and enhanced anti-tumor efficacy in vivo, which may be attributed to the simultaneous inhibition of ribonucleotide reductase and DNA replication in nuclei by the GEM and Pt ions. Together, our work provides a promising strategy in the co-delivery of USPtNs and GEM for precision cancer chemotherapy.


  • Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy

    by Jianhua Zhu, Qiang Huo, Ming Xu, Fen Yang, Yang Li, Huihui Shi, Yimin Niu, Yang Liu

    The treatment of metastatic tumors is highly desirable in clinics, which has also increased the interest in the design of nanoscale drug delivery systems. Bone metastasis is one of the most common pathways in the metastasis of breast cancer, and it is also an important cause for tumor recurrence and death. The aryl boronate group, as an acid-labile linker, has been introduced into nano-assemblies in recent years. Especially, as a proteasome inhibitor anticancer drug with a boric acid group, bortezomib can facilitate the formation of pH-sensitive aryl boric acid ester linkage with the catecholic group. In this study, bortezomib-loaded micelles with bone targeting properties were constructed for the treatment of breast cancer bone metastasis. The mixed micelles employed alendronate (ALN) as the bone-targeting ligand and encapsulated bortezomib-catechol conjugates as the cargo. In vitro and in vivo studies showed that compared with free drugs or control micelles, these prodrug micelles (ALN-NP) exhibited many favorable properties such as reduced systemic toxicity and improved therapeutic effects. Therefore, ALN-NP is promising as a nanovehicle for bone-targeting delivery of chemotherapeutic drugs. Furthermore, this study offers a novel strategy combining bone targeting and aryl boronate-based pH-responsive drug release for anti-metastasis therapy.